BlackSwan Pharma GmbH

Small Molecules - large effect

Welcome

BlackSwan Pharma GmbH is a biopharmaceutical company specialised in novel substances for the treatment of tumours of the blood building system, in particular chronic lymphocytic leukaemia (CLL).

BlackSwan Pharma GmbH is based in the Leipzig BioCity

Our work is based on an exclusive license to both patents and Know-How obtained from The Medicines Company (Leipzig) GmbH for the research and development as well as the marketing of the resulting products. At the current moment, formal preclinical testing is being planned for the first drug candidate, the substance having repeatedly proven its potential for the treatment of CLL in several studies.

Latest News:

30.09.2010 13:02

CD-160130 – a selective tumour hERG channel inhibitor

BlackSwan Pharma announced today exciting news concerning its development candidate CD-160130 resulting from its recent collaboration with Professor Annarosa Arcangeli of the Department of Experimental Pathology and Oncology at the University of Florence (Italy). These findings demonstrate for the first time that selective inhibition of hERG1 channel isoforms can be achieved and may represent an important milestone since the targeting of hERG1 in tumour cells can be seen as a means to both induce apoptosis and also to overcome the resistance to classical chemotherapeutic drugs used for the treatment of leukaemias.